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Abstract
Single nucleotide polymorphisms (SNPs) in the fat mass and obesity associated (FTO) gene are associated with body mass
index (BMI) in populations of European descent. The FTO rs9939609 variant, first detected in a genome-wide association
study of diabetes, conferred an increased disease risk that was abolished after adjustment for BMI, suggesting that the
association may be due to variation in adiposity. The relationship between diabetes, four previously identified FTO
polymorphisms that span a 19.6-kb genomic region, and obesity was therefore evaluated in the biracial population-based
Atherosclerosis Risk in Communities Study with the goal of further refining the association by comparing results between
the two ethnic groups. The prevalence of diabetes and obesity (BMI $30 kg/m
2) was established at baseline, and diabetes
was determined by either self-report, a fasting glucose level $126 mg/dL, or non-fasting glucose $200 mg/dL. There were
1,004 diabetes cases and 10,038 non-cases in whites, and 670 cases and 2,780 non-cases in African-Americans. Differences in
mean BMI were assessed by a general linear model, and multivariable logistic regression was used to predict the risk of
diabetes and obesity. For white participants, the FTO rs9939609 A allele was associated with an increased risk of diabetes
(odds ratio (OR) =1.19, p,0.001) and obesity (OR=1.22, p,0.001) under an additive genetic model that was similar for all
of the SNPs analyzed. In African-Americans, only the rs1421085 C allele was a determinant of obesity risk (OR=1.17,
p=0.05), but was found to be protective against diabetes (OR=0.79, p=0.03). Adjustment for BMI did not eliminate any of
the observed associations with diabetes. Significant statistical interaction between race and the FTO variants suggests that
the effect on diabetes susceptibility may be context dependent.
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Introduction
Diabetes is an important risk factor for cardiovascular disease
[1]. Obesity is an independent risk factor for diabetes [2] and
either BMI or waist-to-hip ratio (WHR) has been commonly used
as a surrogate measure of adiposity. From a public health
perspective, obesity is an accessible target for intervention
programs designed to reduce the incidence of diabetes [3].
The fat mass and obesity associated (FTO) gene maps to
chromosome 16q12.2 and includes nine predicted exons (Genbank
NM 00108432). Genetic variants in FTO have been reported to be
associated with BMI in study populations of European descent
[4,5,6,7,8], although functional polymorphisms in this gene have
not yet been identified. Frayling et al. identified the FTO
rs9939609 SNP in a genome-wide association study comparing
1,924 British type 2 diabetes cases with 2,938 controls [7]. The
minor A allele was found to be strongly associated with diabetes,
while adjustment for BMI in a replication sample abolished the
association with diabetes. FTO is ubiquitously expressed in human
tissues [6,7], with a high level found in the hypothalamus
indicating a possible role in the regulation of appetite or energy
balance. In accordance with this hypothesis, introduction of a Fto
null mutation in mice resulted in postnatal growth retardation, loss
of white adipose tissue, and increased energy expenditure [9]. The
ability of murine Fto to catalyze the demethylation of 3-
methylthymine in single-stranded DNA has also recently been
reported [10]. Although a relationship between FTO polymor-
phisms and obesity has been found in African-American children
[11], there was no association between FTO variants and either
diabetes or obesity in a study of postmenopausal women [12], and
there have been inconsistent results for African-American adults in
three other family-based studies [8,13,14]. To date there have
been no investigations of the association between FTO variants
and diabetes or obesity in a community-based study that included
both African-American men and women.
In this study, the relationship between diabetes, four previously
reported FTO SNPs [6,7,15], and obesity was examined in African-
American and white individuals enrolled in the large prospective
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10521Atherosclerosis Risk in Communities (ARIC) study [16]. Only one of
the genetic variants (rs1421085) was associated with both diabetes
and obesity in African-Americans, while all of the FTO polymor-
phisms were determinants of disease risk in whites as shown in other
studies [4,5,6,7,8,15]. This may reflect differences in linkage
disequilibrium (LD) between the genetic variants in populations of
European and African ancestry [17], as well as the effects of other as
yet uncharacterized gene-gene or gene-environment interactions that
may be distinctive for each racial group.
Results
A description of the study sample stratified by diabetes status
and race is shown in Tables 1 and 2. The values for all clinical
characteristics differed significantly between cases and non-cases
for both whites and African-Americans, except there was a
significantly greater frequency of males in the group of white
diabetes cases when compared to those without diabetes while
there was no relationship between gender and case status for
African-Americans.
The allele and genotype frequencies for all of the FTO
polymorphisms were in accordance with Hardy-Weinberg equilib-
rium expectations for both African-American and white individuals
(p,0.05).TherewasasignificantdifferenceinthefourFTOgenotype
frequencies between diabetes cases and non-cases found for whites,
but a difference was only revealed for rs1421085 in African-Ame-
ricans with the frequency of the minor allele higher in non-cases than
in cases. Similarly, when the frequency of all possible two-, three-,
and four-marker haplotypes was compared between diabetes cases
and non-cases, significant differences were shown for all of the
haplotypes in whites but for none of the marker combinations in
African-Americans (Table S1).
Table 1. Clinical characteristics and FTO SNP genotype frequencies in African-Americans stratified by diabetes case status.
Characteristics Diabetes (n=670) Non-Cases (n=2,780) p
Age, years 55.3 (5.6)
a 53.1 (5.8)
a ,0.001
Male (%) 35.7 38.7 0.147*
European ancestry (%) 16.7 18.1 0.002
BMI (kg/m
2) 32.0 (6.1)
a 29.0 (6.0)
a ,0.001
DBP, mm Hg 78.3 (12.0)
a 80.0 (12.2)
a ,0.001
SBP, mm Hg 133.3 (22.9)
a 127.7 (20.8)
a ,0.001
HDL, mg/dL 48.8 (15.0)
a 56.3 (17.8)
a ,0.001
LDL, mg/dL 143.6 (45.0)
a 135.9 (42.0)
a ,0.001
Glucose, mg/dL 199.7 (89.9)
a 98.7 (10.1)
a ,0.001
Insulin, pmol/L 342.8 (632.4)
a 94.8 (69.9)
a ,0.001
FTO SNP Genotype/Allele n % n % p
rs9939609 TT 197 30.1 734 27.3 0.364 *
AT 310 47.3 1,309 48.8
AA 48 22.6 642 23.9
T 704 53.7 2,777 51.7
A 606 46.3 2,593 48.3
rs17817449 TT 258 39.5 996 36.9 0.413*
GT 299 45.8 1,270 47.0
GG 96 14.7 434 16.1
T 815 62.4 3,262 60.4
G 491 37.6 2,138 39.6
rs805136 CC 225 34.2 861 31.6 0.403*
AC 306 46.6 1,334 48.9
AA 126 19.2 533 19.5
C 756 57.5 3,056 56.0
A 558 42.5 2,400 44.0
rs1421085 TT 551 83.9 2,153 79.0 0.014*
CT 101 15.4 531 19.5
CC 5 0.8 41 1.5
T 1,203 91.6 4,837 88.8
C 111 8.4 613 11.2
n, number; p, p-value, significance of difference between group means determined by t-test; BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood
pressure; HDL, high density lipoprotein; LDL, low density lipoprotein;
amean and standard deviation; SNP, single nucleotide polymorphism;
*p-value Pearson chi-squared.
doi:10.1371/journal.pone.0010521.t001
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significant variation in mean BMI between those with different
FTO genotypes (Table 3). There was a significant difference found
for white participants for all polymorphisms studied but only for
rs17817449 and rs1421085 in African-Americans, although the
trend in both racial groups was for increasing BMI with each
addition of an FTO risk allele. There was also a significant
difference found in mean WHR and waist circumference (WC) for
white but not for African-American individuals categorized by FTO
genotype, while there was no apparent variation in mean height
with genotype for either racial group. Sex-specific analyses were
carried out (data not shown) and variation in the effect of the FTO
SNPs on obesity-related quantitative traits by gender was not
observed with the exception of higher mean BMI found for
African-American females (p=0.02) but not for males (p=0.55)
with addition of a rs1421085 C allele.
BMI was also evaluated as a categorical variable using standard
criteria [18] (Table 4). When a BMI $30 kg/m
2 was used to
define obesity and logistic regression models were adjusted for age
and gender, addition of an FTO rs1421085 C allele conferred an
elevated risk of being obese for both white and African-American
participants. The remaining 3 FTO polymorphisms were signifi-
cantly associated with obesity in whites but not in African-
Americans. If this association was examined separately by gender,
the risk of obesity was similar for both sexes for white participants
for all of the polymorphisms, while a significantly increased risk of
obesity was found for African-American males but not for females
for rs9939609 (males, OR=1.27, p=0.01; females, OR=1.00,
p=0.95) and rs17817449 (males, OR=1.19, p=0.05; females,
OR=1.06, p=0.36) with evidence for gender by gene interaction
for rs9939609 (OR for interaction =1.27, p=0.03). Application
of a polytomous logistic model revealed a significant association
between the 4 FTO genetic variants and BMI across all categories
for white participants when compared to individuals whose BMI
was ,25 kg/m
2, while this pattern was not observed for African-
American subjects.
Table 2. Clinical characteristics and FTO SNP genotype frequencies in whites stratified by diabetes case status.
Characteristics Diabetes (n=1,004) Non-Cases (n=10,038) p
Age, years 56.2 (5.6)
a 54.2 (5.7)
a ,0.001
Male (%) 53.0 46.6 ,0.001*
BMI (kg/m
2) 30.4 (5.7)
a 26.7 (4.6)
a ,0.001
DBP, mm Hg 72.9 (10.9)
a 71.4 (10.0)
a ,0.001
SBP, mm Hg 126.8 (18.4)
a 117.6 (16.6)
a ,0.001
HDL, mg/dL 41.4 (13.9)
a 51.4 (16.8)
a ,0.001
LDL, mg/dL 140.1 (39.2)
a 137.3 (37.7)
a 0.032
Glucose, mg/dL 174.7 (70.6)
a 98.6 (9.0)
a ,0.001
Insulin, pmol/L 222.7 (433.6)
a 72.6 (54.3)
a ,0.001
FTO SNP Genotype/Allele n % n % p
rs9939609 TT 314 31.8 3,566 36.0 0.001*
AT 472 47.8 4,739 47.8
AA 202 20.4 1,610 16.2
T 1,100 55.7 11,871 59.9
A 876 44.3 7.959 40.1
rs17817449 TT 312 31.6 3,565 35.8 0.002*
GT 474 48.1 4,752 47.8
GG 200 20.3 1.631 16.4
T 1,098 55.7 11,882 59.7
G 874 44.3 8,014 40.3
rs805136 CC 311 31.6 3,545 35.9 0.001*
AC 473 48.1 4,714 47.8
AA 200 20.3 1,614 16.3
C 1,095 55.6 11,804 59.8
A 873 44.4 7,942 40.2
rs1421085 TT 304 30.8 3,461 35.0 0.001*
CT 477 48.2 4,759 48.1
CC 208 21.0 1,673 16.9
T 1,085 54.8 11,681 59.0
C 893 45.2 8,105 41.0
n, number; p, p-value, significance of difference between group means determined by t-test; BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood
pressure; HDL, high density lipoprotein; LDL, low density lipoprotein;
amean and standard deviation; SNP, single nucleotide polymorphism;
*p-value Pearson chi-squared.
doi:10.1371/journal.pone.0010521.t002
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the association of sequence variation in the FTO gene and diabetes
case status. These results are presented in Table 5. After adjusting
for age and gender, all of the FTO risk alleles were significantly
associated with an increased susceptibility for diabetes in white
individuals. Adjustment for age, gender, as well as BMI attenuated
but did not abolish the risk for diabetes.
In contrast to the results described above for whites, three of the
FTO SNPs were not significantly associated with diabetes case
status for African-American participants in the ARIC study
(Table 5). However, a significant protective effect of the
rs142105 C allele was observed that was still evident after
adjustment for BMI. When multivariable logistic regression was
performed to examine the influence of the FTO gene on diabetes
risk after combining African-American and white participants and
adjusting for age, gender, and race, significant interaction between
all of the FTO genetic variants and race was detected (p-value for
interaction =0.001, 0.001, 0.002, and ,0.001 for rs9939609,
rs17817449, rs805136, and rs1421085, respectively).
Discussion
The relationship between diabetes, four previously identified
FTO polymorphisms, and obesity was evaluated in the biracial
population-based ARIC cohort study in an initial effort to fine
map the association by comparing results between two racial
groups. The assumption underlying the performance of these
analyses was that since functional SNPs in FTO have not yet been
identified, the detection of genetic variants that are significantly
associated with obesity and diabetes in multiple ethnic or racial
groups may help to further define the relevant genomic region or
potential candidate causative mutations. In this study, all of the
FTO polymorphisms were associated with elevated risk for diabetes
and obesity in white participants, while addition of the rs1421085
C allele was a determinant of increased susceptibility to obesity in
African-Americans but conferred a protective effect against
diabetes.
Although Frayling et al. found that the association of the FTO
gene and diabetes was mediated by BMI in a genome-wide
association study of British diabetes cases and controls [7], the
results for this cohort suggest that the gene plays a role in the
susceptibility to diabetes that cannot entirely be accounted for by
its effect on body size. The attenuation but not elimination of risk
for diabetes after adjusting for BMI in whites may reflect the fact
that a single BMI measurement in prevalent cases may not fully
capture the effect of FTO on adiposity and metabolism. The
protective effect of the rs1421085 C allele was more marked after
adjustment for BMI in African-Americans. For both racial groups,
Table 3. Association of FTO genotype and quantitative traits stratified by race.
SNP Genotype BMI (AA) p* WHR (AA) p* Waist (AA) p* Height (AA) p*
rs9939609 TT 29.4 (6.2)
a 0.22 0.918 (0.076) 0.82 98.7 (15.2) 0.27 167.9 (9.2) 0.63
AT 29.6 (6.2) 0.919 (0.075) 99.1 (15.3) 168.2 (8.9)
AA 29.8 (5.9) 0.919 (0.076) 99.5 (14.8) 168.2 (8.8)
rs17817449 TT 29.4 (6.1) 0.05 0.918 (0.075) 0.75 98.6 (14.9) 0.07 167.9 (9.0) 0.38
GT 29.5 (6.1) 0.918 (0.077) 98.9 (15.1) 168.2 (8.9)
GG 30.0 (6.2) 0.920 (0.073) 100.1 (15.6) 168.4 (8.8)
rs8050136 CC 29.6 (6.2) 0.48 0.919 (0.076) 0.77 99.1 (15.2) 0.58 167.8 (8.9) 0.59
AC 29.5 (6.2) 0.918 (0.076) 98.8 (15.2) 168.2 (8.9)
AA 29.8 (6.0) 0.919 (0.075) 99.6 (15.0) 168.2 (8.8)
rs1421085 TT 29.5 (6.1) 0.02 0.918 (0.076) 0.39 99.0 (15.0) 0.09 168.0 (8.9) 0.48
CT 29.7 (6.3) 0.919 (0.074) 99.1 (15.3) 168.1 (9.0)
CC 30.3 (6.7) 0.926 (0.074) 101.4 (16.0) 170.1 (9.0)
BMI (W) p* WHR (W) p* Waist (W) p* Height (W) p*
rs9939609 TT 26.6 (4.6) ,0.001 0.924 (0.079) ,0.001 95.2 (12.9) ,0.001 168.7 (9.4) 0.67
AT 27.1 (4.9) 0.929 (0.079) 96.4 (13.4) 168.5 (9.4)
AA 27.5 (5.1) 0.935 (0.078) 97.7 (13.9) 168.8 (9.4)
rs17817449 TT 26.6 (4.6) ,0.001 0.924 (0.080) ,0.001 95.2 (13.0) ,0.001 168.7 (9.4) 0.89
GT 27.1 (4.9) 0.929 (0.079) 96.4 (13.5) 168.5 (9.4)
GG 27.5 (5.1) 0.935 (0.078) 97.6 (13.9) 168.8 (9.4)
rs8050136 CC 26.6 (4.6) ,0.001 0.924 (0.080) ,0.001 95.2 (13.0) ,0.001 168.7 (9.4) 0.79
AC 27.1 (4.9) 0.929 (0.079) 96.4 (13.5) 168.5 (9.4)
AA 27.5 (5.1) 0.935 (0.078) 97.7 (13.9) 168.8 (9.4)
rs1421085 TT 26.6 (4.6) ,0.001 0.924 (0.79) ,0.001 95.1 (13.0) ,0.001 168.7 (9.4) 0.75
CT 27.1 (4.9) 0.924 (0.79) 96.5 (13.5) 168.5 (9.4)
CC 27.5 (5.1) 0.934 (0.078) 97.6 (13.9) 168.8 (9.4)
SNP, single nucleotide polymorphism; BMI, body mass index; AA, African-American; p, p-value, significance of differences in means of obesity-related quantitative traits
among individuals categorized by FTO genotype;
*adjusted for age and gender in white participants, and for age, gender, and percentage European ancestry in African-American participants; WHR, waist-to-hip ratio;
amean and standard deviation; W, white.
doi:10.1371/journal.pone.0010521.t003
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by Frayling et al. [7] for the Wellcome Trust Case Control
Consortium but were similar to the results found for participants in
the Finland-United States Investigation of the Non-Insulin-
Dependent Diabetes Mellitus Genetics (FUSION) study in another
early genome-wide association analysis of diabetes risk [15,19].
Genetic variants in the FTO gene have consistently been
reported to be associated with BMI [4,5,6,7,8] and diabetes [7,15]
in Europeans, but the results have been variable for replication in
other ethnicities including Hispanics [8,12,14], Asian and Oceanic
populations [12,20,21,22,23,24,25,26,27,28,29,30,31], and Afri-
can-Americans [8,11,12,13,14]. In a case-control study of FTO
and childhood obesity defined as a BMI $95
th percentile, only
rs3751812 was shown to confer significant risk in African-
American members of the cohort, while 7 out of the 13 SNPs
genotyped were significantly associated with the same trait in
Caucasians. As in the case of rs1421085 in the current study
(Tables 1, 2, and S2), rs3751812 is not in strong LD in HapMap
Table 4. Association of FTO and obesity or BMI stratified by race.
SNP BMI kg/m
2 AA % OR 95% CI p* White % OR 95% CI p*
rs9939609 Obese ($30) 1,346 40.3 1.09 0.98–1.20 0.10 2,470 22.6 1.22 1.14–1.30 ,0.001
,25 730 21.9 { 4,065 37.3 {
25–29 1,264 37.8 1.01 0.89 –1.15 0.86 4,368 40.0 1.08 1.02–1.15 0.02
30–40 1,154 34.5 1.10 0.96–1.26 0.15 2,276 20.9 1.27 1.18–1.37 ,0.001
.40 192 5.8 1.04 0.83–1.31 0.70 194 1.8 1.23 1.00 –1.51 0.05
rs17817449 Obese ($30) 1,346 40.1 1.10 1.00–1.22 0.06 2,473 22.6 1.20 1.13–1.28 ,0.001
,25 741 22.1 { 4,087 37.4 {
25–29 1,266 37.8 0.98 0.86–1.11 0.73 4,374 40.0 1.09 1.02–1.16 0.01
30–40 1,155 34.4 1.08 0.95–1.24 0.24 2,276 20.8 1.26 1.17–1.36 ,0.001
.40 191 5.7 1.09 0.86–1.38 0.47 197 1.8 1.26 1.03–1.55 0.02
rs8050136 Obese ($30) 1,362 40.2 1.04 0.94–1.15 0.42 2,470 22.8 1.21 1.13–1.29 ,0.001
,25 741 21.9 { 4,050 37.3 {
25–29 1,282 37.9 1.02 0.89 –1.16 0.80 4,337 40.0 1.10 1.03–1.17 0.01
30–40 1,167 34.5 1.06 0.93–1.21 0.40 2,275 20.9 1.27 1.18–1.37 ,0.001
.40 195 5.7 1.00 0.81–1.28 0.90 195 1.8 1.25 1.02–1.54 0.03
rs1421085 Obese ($30) 1,358 40.2 1.17 1.00–1.38 0.05 2,471 22.7 1.22 1.15–1.30 ,0.001
,25 739 21.9 { 4,059 37.3 {
25–29 1,285 38.0 1.02 0.83–1.26 0.83 4,352 40.0 1.10 1.03–1.17 0.01
30–40 1,164 34.4 1.18 0.95 –1.47 0.13 2,273 20.9 1.28 1.19–1.38 ,0.001
.40 194 5.7 1.25 0.86 –1.81 0.24 198 1.8 1.26 1.03–1.54 0.03
SNP, single nucleotide polymorphism; BMI, body mass index; AA, African-American; OR, odds ratio; CI, confidence interval; p, p-value for multivariable logistic regression
(additive genetic model) used to predict risk of obesity (BMI $30 kg/m
2), or for polytomous logistic regression used across categories of BMI with BMI ,25 kg/m
2 as the
common reference;
*adjusted for age and gender in white participants, and for age, gender, and percentage European ancestry in African-American participants;
{, referent group.
doi:10.1371/journal.pone.0010521.t004
Table 5. Association of FTO risk alleles and diabetes stratified by race.
FTO SNP Race Subjects (n) Diabetes (n) % OR
1 95% CI p OR
2 95% CI p
rs9939609 AA 3,340 655 19.6 0.92 0.82–1.04 0.18 0.91 0.80–1.03 0.12
White 10,903 988 9.1 1.19 1.09–1.31 ,0.001 1.12 1.02–1.23 0.02
rs17817449 AA 3,353 653 19.5 0.92 0.81–1.04 0.17 0.89 0.79 –1.02 0.08
White 10,934 986 9.0 1.18 1.08–1.30 ,0.001 1.11 1.01–1.22 0.03
rs8050136 AA 3,385 657 19.4 0.94 0.83–1.06 0.34 0.94 0.83–1.06 0.29
White 10,882 984 9.1 1.19 1.08–1.31 ,0.001 1.12 1.01–1.23 0.02
rs1421085 AA 3,382 657 19.4 0.79 0.64 –0.98 0.03 0.75 0.60 –0.93 0.01
White 10,857 989 9.1 1.19 1.09–1.31 ,0.001 1.12 1.01–1.23 0.02
SNP, single nucleotide polymorphism; n, number; OR
1, odds ratio, adjusted for age and gender in white participants, and for age, gender, and percentage European
ancestry in African-American participants; CI, confidence interval; OR
2, odds ratio, adjusted for age, gender, and BMI in white participants, and for age, gender, BMI, and
percentage European ancestry in African-American participants; p, p-value for multivariable logistic regression (additive genetic model); AA, African-American.
doi:10.1371/journal.pone.0010521.t005
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identified in Europeans (r
2=0.072 in Yoruba in Ibadan, Nigeria
(YRI); r
2=0.119 in African ancestry in southwest USA (ASW)),
and the minor allele frequency (MAF) was not the same for white
and African-American participants enrolled in the cohort (MAF
for rs3751812 =0.443 and 0.115 in Caucasian and African-
Americans, respectively), indicating that this polymorphism may
be associated differently with a putative causative variant in the
two racial groups [11]. In contrast, when 27 FTO variants were
genotyped in 604 African-American subjects enrolled in the
Insulin Resistance Atherosclerosis Family Study, both rs9939609
and rs8050136 were significantly associated with BMI and WC,
but no association was observed for either rs3751812 or rs1421085
[14]. Scuteri et al. carried out a genome-wide association scan in
6,148 individuals from a genetically isolated population in
Sardinia and identified 8 SNPs within the FTO gene that were
associated with increased BMI, hip circumference, and weight.
When either the SNP that was most highly associated with all 3
quantitative traits in Sardinia (rs9930506) or 7 additional SNPs
were genotyped in 1,101 African-American participants in the
GenNet study, there was no evidence for association with BMI.
The authors suggested that because the MAF for some of the FTO
variants tested, including rs1421085, was lower in African-
Americans than in European Americans, increased sample sizes
would be required to assess their effects [8]. A similar difference in
allele frequency was observed in the study reported here (MAF for
rs1421085 =0.41 and 0.11 in whites and African-Americans,
respectively) while the study population examined was consider-
ably larger (n=3,450 African-Americans), possibly enabling the
detection of an association between this variant and an obesity-
related quantitative trait in the ARIC cohort. There was also no
association observed between 2 FTO polymorphisms (rs9939609
and rs8050136) and obesity, BMI, WC, or diabetes in African-
American participants in a nested case-control study of postmen-
opausal women from the Women’s Health Initiative-Observation-
al Study [12], or between FTO variants and either BMI or weight
in a genome-wide association study that included a group of 1,160
African-Americans in the discovery sample [13].
Evidence of statistical interaction between race and the FTO
polymorphism shown after combining African-American and
white participants further suggests that the influence of the FTO
gene on diabetes susceptibility may be context dependent. There
are a number of potential explanations for the difference in the
impact of this gene on disease risk in white and African-American
participants in the ARIC study where there was adequate power to
detect an effect of the same magnitude (OR=1.15–1.27)
previously reported for Europeans [7,15,19] (Table S3). One
factor may be the degree of LD between the polymorphisms since
all of the FTO SNPs are highly correlated (r
2.0.90) in whites of
European descent (CEU) whereas the strength of LD across the
19.6-kb region within intron 1 is reduced in populations with
African ancestry included in the International HapMap project
[17] (Table S2). The contribution of all four of the SNPs to
increased diabetes risk in whites is in accordance with the LD
pattern in the region so that the analysis of each of the variants
would be expected to yield a similar measure of association. In
addition, the differences in LD among the SNPs when whites are
compared to African-Americans could lead to the observed results
if the true causative mutation is in turn correlated with the four
FTO variants examined in whites but only with rs1421085 in
African-Americans. Another possibility is that if the relationship
between FTO sequence variation and diabetes is at least partially
mediated by BMI, the nominally significant p-value found for the
association of rs1421085 with obesity and the absence of
association for the remaining variants in African-Americans may
make an increase in diabetes susceptibility more difficult to detect.
Alternatively, although it is necessary to treat this speculation with
considerable caution, the genetic architecture of diabetes may
differ in the two ethnic groups. Detection of a protective effect of
the rs1421085 C allele against diabetes in African-Americans
while risk is increased in whites, even though the same allele
marginally increases susceptibility to obesity in both racial groups,
provides some support for this view. Finally, variation in other
genetic or environmental factors that contribute to the develop-
ment of type 2 diabetes may underlie the apparently disparate
effects of the FTO gene in African-Americans and whites in the
ARIC cohort. More extensive genotyping of common polymor-
phisms in other populations combined with genomic sequencing
strategies to catalog the contribution of rare variants will be
required to confirm the observed racial differences in the effect of
the FTO SNPs on diabetes susceptibility, and may help to
distinguish between these various possibilities.
Materials and Methods
Ethics Statement
All individuals enrolled in the ARIC study provided written
informed consent, and the study design and methods were
approved by institutional review boards at the four collaborating
medical centers: University of Mississippi Medical Center
Institutional Review Board (Jackson Field Center); Wake Forest
University Health Sciences Institutional Review Board (Forsyth
County Field Center); University of Minnesota Institutional
Review Board (Minnesota Field Center); and the Johns Hopkins
School of Public Health Institutional Review Board (Washington
County Field Center).
Atherosclerosis Risk in Communities (ARIC) Study
The ARIC Study is a prospective longitudinal investigation of
the development of atherosclerosis and its clinical sequelae
involving 15,792 individuals aged 45 to 64 years at baseline
selected by probability sampling from four communities in the
United States. A detailed description of the ARIC Study has been
reported previously [16]. At the inception of the study in 1986–
1989, the participants were recruited from Forsyth County, North
Carolina; Jackson, Mississippi (African-Americans only); the
northwestern suburbs of Minneapolis, Minnesota; or Washington
County, Maryland. Four examinations have been carried out at
three-year intervals (exam 1, 1987–1989; exam 2, 1990–1992;
exam 3, 1993–1995; exam 4, 1996–1998), and subjects are
contacted annually to update their medical histories between
examinations. Individuals were excluded from this analysis if they
restricted use of their DNA (n=44), were African-Americans from
the Minnesota or Maryland field centers because of the small
numbers of individuals recruited from these sites (n=55), were
neither African-American nor white (n=48), or were missing all
FTO genotypes (n=599), diabetes case status (n=102), BMI
(n=12), WC (n=3), WHR (n=4), or estimated percentage
European ancestry (n=433). The final study sample consisted of
14,492 participants.
Clinical and Laboratory Measurements at the Baseline
Examination
The prevalence of diabetes was determined at the baseline
examination using a fasting glucose level $126 mg/dl, a
nonfasting glucose level $200 mg/dl, and/or self-reported
physician diagnosis or treatment for diabetes. Body weight and
other anthropometric variables were measured by trained
FTO, Diabetes, and Obesity
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calculated as weight in kilograms/(height in meters)
2 and obesity
was defined as BMI $30. WHR was calculated as waist girth in
cm/hip girth in cm. Blood pressure was measured three times
while seated using a random-zero sphygmomanometer and the last
two measurements were averaged for analysis. Plasma total
cholesterol was measured by an enzymatic method [32] and low
density lipoprotein (LDL) cholesterol was calculated [33]. High
density lipoprotein (HDL) cholesterol was measured after dextran-
magnesium precipitation of non-HDL [34]. Fasting serum glucose
was measured by a standard hexokinase method on a Coulter
DACOS chemistry analyzer (Coulter Instruments, Fullerton, CA,
USA) and the fasting serum insulin level was assessed by
radioimmunoassay (
125Insulin Kit, Cambridge Medical Diagnos-
tics, Billerica, MA, USA).
Genotype Determination
Genotyping of the FTO polymorphisms was performed using
the TaqMan assay (Applied Biosystems, Foster City, CA, USA).
Sequences for primers and TaqMan probes are available upon
request. Allele detection was performed using the ABI Prism 7700
Sequence Detection System (Applied Biosystems). The genotype
call rate, or the percentage of samples to which a genotype was
assigned, was determined prior to exclusion of individuals from the
analysis and ranged from 94.4% for rs9939609 and rs8050136 to
94.7% for rs1781744. After the application of all exclusion criteria,
the proportion of missing genotype data in the final study sample
did not exceed 2.5% for any of the genetic variants. The
genotyping success rate was also assessed by analyzing the
concordance between genotypes for pairs of blind duplicates
included with the DNA samples from the study participants.
Kappa coefficients [35], an index of the percent agreement
between measurements corrected for agreement occurring by
chance, were calculated for each SNP and ranged from 0.97 to
0.98.
Statistical Analysis
All statistical analyses were performed using Stata 9 software
(StataCorp, College Station, TX, USA). Hardy-Weinberg equi-
librium was tested using a x
2 goodness-of-fit test for all individuals
in each racial group. The proportions, means and standard
deviations were calculated for established risk factors for diabetes
for both the prevalent diabetes cases and for the comparison
groups. Multivariable logistic regression was used to evaluate the
relationship between diabetes case status, the FTO alleles, and
measures of obesity under an additive genetic model. Tests of
interaction were conducted by including main effects for each FTO
polymorphism and gender or race in the logistic regression
models, and introducing a multiplicative two-way interaction term
for gene by gender or gene by race. Prevalence odds ratios (OR)
were adjusted for age and gender for white participants, and age,
gender, and percentage European ancestry for African-American
participants [36]. Percentage European ancestry was determined
by performing a genome-wide admixture mapping scan using a
panel of 1,350 ancestry informative markers and the Illumina
BeadLab platform (Illumina, San Diego, CA, USA). Global
ancestry was estimated using ANCESTRYMAP software [37].
General linear models were used to assess mean differences in
BMI, WHR, and WC among FTO SNP genotypes. A p-value
,0.05 was considered statistically significant. The results of all
statistical analyses are reported separately by self-reported racial
group.
Supporting Information
Table S1 Haplotype analysis stratified by race.
Found at: doi:10.1371/journal.pone.0010521.s001 (0.04 MB
DOC)
Table S2 Linkage disequilibrium (LD) between FTO SNPs in
HapMap populations.
Found at: doi:10.1371/journal.pone.0010521.s002 (0.05 MB
DOC)
Table S3 Prevalence odds ratios for diabetes and obesity case
status detectable at 80% power stratified by race.
Found at: doi:10.1371/journal.pone.0010521.s003 (0.03 MB
DOC)
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